G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder by Niehans, G A et al.
To acquire a neoplastic phenotype, cells must disable multiple
regulatory mechanisms including cell cycle control (Strauss et al,
1995). Abrogation of the G1 cell cycle checkpoint occurs in
many malignancies. Key components of the checkpoint include
retinoblastoma protein (Rb), cyclin D1 (also known as bcl-1 and
PRAD-1), and the cyclin-dependent kinase inhibitor p16INK4a. In
normal cells, the Rb protein acts as a cell cycle brake while in its
active, hypophosphorylated state. Cyclin D1 is a short-lived
protein with a half-life of 30 min or less. When cyclin D1 is
induced in early G1 by mitogenic signals such as growth factors, it
binds to and activates the cyclin-dependent kinases CDK4 and
CDK6, and these cyclin–kinase complexes then phosphorylate and
inactivate the Rb protein, allowing the cell to proceed into S phase
(reviewed by Strauss et al, 1995). p16INK4a binds to CDK–cyclin
complexes and blocks phosphorylation of the Rb protein. Since
inactivation of Rb enhances transcription of p16INK4a, p16INK4a may
act in normal cells as part of a negative feedback loop to turn off
CDK4–cyclin D activity once the cell has passed the G1 restriction
point (Serrano et al, 1993; Li et al, 1994; Parry et al, 1995). Thus,
inactivation of either p16INK4a or Rb protein shifts the balance
toward continued cell proliferation, as does amplification/overex-
pression of cyclin D1.
Abnormalities of individual components of the Rb/cyclin
D1/p16INK4a pathway have been previously reported in cases of
transitional cell carcinoma of the bladder (Cordon-Cardo et al,
1992; Logothetis et al, 1992; Geradts et al, 1995; Gruis et al, 1995;
Orlow et al, 1995; Packenham et al, 1995; Williamson et al, 1995;
Bringuier et al, 1996; Lee et al, 1997; Shin et al, 1997). In order to
assess the overall frequency of G1 checkpoint defects in bladder
carcinoma, and to examine the interrelationship between abnor-
malities in component proteins, we studied a series of 79 transi-
tional cell carcinomas for evidence of cyclin D1 overexpression or
loss of Rb or p16INK4a proteins, using immunohistochemistry. The
p53 status of these tumours was also assessed via immunohisto-
chemistry, since p53 influences cell cycle control through an inde-
pendent pathway mediated by p21WAF1/CIP1 (El-Deiry et al, 1993).
MATERIALS AND METHODS
Case selection and patient information
Most cases (77 of 79) were drawn from a previously published
series (Nguyen et al, 1994) of 91 invasive transitional cell carci-
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between April 1975 and December 1989. Fourteen of the original
91 cases did not have sufficient residual tumour tissue in paraffin
blocks to allow for further studies. Two new cases were added to
the current series because of the acquisition of clinical and follow-
up data not available at the time that the previous series was
assembled. Nine cases were included in a previous report exam-
ining Rb and p16INK4a expression in archival human solid tumours
(Geradts et al, 1995). All cases were staged according to the TNM
system as specified by the American Joint Committee on Cancer
(American Joint Committee on Cancer, 1992), and assigned a
histological grade of 2–4 using Ash’s criteria as outlined by Rosai
(1996). Grade 1 was not assigned in this series since all tumours
were invasive, and since only two carcinomas were assigned a
grade of 2, grades 2 and 3 carcinomas were considered together in
analyses. Seventeen patients had received adjuvant perioperative
radiation therapy, 13 patients received adjuvant chemotherapy, and
17 received both. Because the administration of adjuvant therapy
was nonrandomized (i.e. it was prescribed at the discretion of indi-
vidual physicians for patients whom they judged to be at high risk
of recurrence), and because a wide variety of regimens were
employed, we did not stratify patient groups according to adjuvant
status in the survival analysis. We did test adjuvant and non-adju-
vant groups for imbalances with regards to cell cycle variables, to
look for a source of introduced bias. Adjuvant and non-adjuvant
groups were balanced with respect to p53, Rb, p16 and p16+Rb
status. Adjuvant therapy was less likely to have been administered
to patients with cyclin D1-overexpressing tumours, presumably
because of the association between cyclin D1 overexpression and
lower tumour grade (see Results and Discussion sections below).
If adjuvant therapy were expected to improve survival, then the
observed imbalance would strengthen and not weaken the associa-
tion between cyclin D1 overexpression and favourable prognosis.
The mean patient age, mean and median follow-up times after
surgery, and stage and grade of the 79 cases are shown in Table 1.
Patient information was obtained from the Minneapolis Veterans
Administration Medical Center Tumour Registry and from chart
review. All cases were transitional cell carcinomas; other
morphologies were excluded at the time of the selection of the
original series. Seventy-eight patients were male and one was
female (reflecting the patient population served at our institution).
Only three living patients were lost to follow-up during the course
of the study (at 0, 10 and 46 months respectively). There were four
post-operative deaths due to infection or perioperative myocardial
infarct, with no residual cancer at the time of death. Twenty-seven
additional patients died of causes unrelated to bladder cancer
during the course of the study, with four of those deaths occurring
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Table 1 Clinical and pathologic characteristics of 79 invasive transitional cell carcinomas of the
urinary bladder treated by cystectomy
Mean age (years) at time of diagnosis 64.7, range 48–82 (median 65)
Mean follow-up (months) since surgery (survivors) 100.6, range 0–214 (median 94)
Mean follow-up (months) since surgery 44.1, range 1–134 (median 57)
(patients who died during study)
Pathologic stagea of tumours [TNM] (n = 79)
Ib 15
II 18
III 23
IV 23
Pathologic grade of tumours [Ash] (n = 79)
10
22
35 4
42 3
EGFR index (n = 77)c
High 28
Low 49
PCNA percentage (n = 76)a,c
High 42
Low 34
DNA ploidy status (n = 61)c
Diploid 30
Aneuploid 31
S phase fraction (n = 35)c
High 14
Low 21
EGFR, epidermal growth factor receptor; PCNA, proliferating cell nuclear antigen. aTumours were
staged according to the American Joint Committee on Cancer (1992) Manual for Staging Cancer, 4th
edn. bAll Stage 1 tumours in this study were T1 lesions. Non-invasive Ta/Tis lesions were excluded.
cEGFR index, PCNA percentage, DNA ploidy status, and S-phase fraction were determined in a
previous publication (Nguyen et al, 1994).during the first year after cystectomy. Twenty-five patients died
with or due to bladder cancer. Finally, 20 patients were alive and
being followed at the time that the study concluded; no patients
were living with disease. The follow-up period for these disease-
free survivors ranged from 64 to 214 months (mean 112.9 months,
median 95 months). The mean follow-up time for all survivors
(including those lost to follow-up while alive) was 100.6 months
(median, 94 months). The length of follow-up for patients who
died during the course of the study ranged from 1 to 134 months
(mean, 44.1 months, median 28.5 months).
Drawing on the results of our previous study (Nguyen et al,
1994), information on epidermal growth factor receptor (EGFR)
status was available for 77 cases, percentage of proliferating cell
nuclear antigen (PCNA)-positive tumour cells for 76 cases, ploidy
status for 61 cases, and S phase fraction for 35 cases. These data
are also presented in Table 1.
Immunohistochemistry
The Rb antibody used in this study, 3C8, was obtained from Canji
Inc. (San Diego, CA, USA), and used at a dilution of 1 mg ml–1 for
1 h, following an epitope retrieval step using hot citrate buffer.
Immunohistochemical staining was carried out as previously
described (Geradts et al, 1996). A polyclonal p16INK4a antiserum
obtained from PharMingen (San Diego, CA, USA), was applied to
all bladder carcinomas, at a dilution of 1:400 overnight, using a
previously described protocol (Geradts et al, 1995). For equivocal
cases, follow-up p16INK4a staining was performed with a mono-
clonal antibody, G175-405 (2 mg ml–1), from PharMingen; tissues
were incubated overnight with the antibody after epitope retrieval
with hot citrate buffer. p53 immunostaining utilized the D07 anti-
body (Dako, Carpinteria, CA, USA) at a dilution of 1:200, using a
previously published procedure (Resnick et al, 1995). A cyclin
D1 antibody (clone P2D11F11) was obtained from Vector
Laboratories (Burlingame, CA, USA acting as US distributor for
Novocastra Laboratories, Newcastle-upon-Tyne, UK) and used at
a dilution of 1:1000. For cyclin D1, we utilized epitope retrieval in
which deparaffinized and rehydrated 4-micron tissue sections were
placed in Coplin jars containing 10 mM citrate buffer, pH 6, and
boiled for 10 min in a 6-liter pressure cooker (Decor USA,
Palatine, IL, USA) at 12 pounds per square inch. After cooling, the
slides were rinsed in 0.01 M phosphate-buffered saline (PBS), pH
7.4, and incubated for 15 min with 15 ml ml–1 horse serum to block
non-specific binding. After an overnight incubation at 4°C with
the primary antibody, the slides were immunolabelled by an
avidin–biotin–peroxidase complex technique, utilizing the Vector
mouse Elite ABC kit (Vector Laboratories, Burlingame, CA,
USA), according to manufacturers’ instructions. Chromogenic
development was accomplished by incubation with 0.5 mg ml–1
3,3¢-diaminobenzidine tetrahydrochloride (DAB) containing
0.009% hydrogen peroxide, and terminated after 5 min by a tap
water rinse. Slides were then counterstained in haematoxylin and
coverslipped.
The following external positive controls were used: mesothe-
lioma cell line H2373 for Rb (p16–Rb+); lung cancer cell lines
H417 and H2009 (p16+Rb–), as well as a nude mouse xenograft of
H2009 cells, for p16INK4a. In addition, non-neoplastic cells provided
positive internal controls in every section of tumour. A lung carci-
noma with a known mis-sense mutation in p53 was utilized as a
p53-positive control, while a cyclin D1 overexpressing squamous
carcinoma of the head and neck served as a control for cyclin D1. In
addition, sections were reacted with non-specific mouse IgG and
rabbit serum, respectively, as negative controls.
Interpretation of stains
All immunohistochemical stains were evaluated independently by
two pathologists (GN and JG evaluated Rb, p16INK4a and p53 stains,
while GN and KF evaluated cyclin D1 slides). Differences in inter-
pretation were reconciled by rereview of slides separately or jointly
at a double-headed microscope. Rb and p16INK4a were evaluated
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Figure 1 Patterns of p16INK4a expression in transitional cell carcinomas.
(A) p16 -negative tumour. Absence of staining in invasive carcinoma (arrow
heads) with preserved reactivity in surrounding stromal cells (arrows).
(B) p16-positive tumour (‘low’). Note weak to moderate nuclear staining in
less than 50% of neoplastic cells, associated with moderate cytoplasmic
background reactivity. (C) p16-positive tumour (‘high’). Note strong nuclear
staining in over 90% of neoplastic cells, associated with moderate
cytoplasmic background reactivity. Original magnification 4003 (A–C)using previously described criteria (Geradts et al, 1995; Geradts et
al, 1996). Only nuclear staining was evaluated; cytoplasmic reac-
tivity, if present, was disregarded. A tumour was considered normal
(positive) for Rb or p16INK4a if there was distinct nuclear staining in
all areas of the lesion. A tumour was considered abnormal if there
was no definite nuclear staining within the malignant cells with
preserved nuclear reactivity in admixed non-neoplastic cells. In a
small number of tumours, loss of Rb or p16INK4a was restricted to a
defined area within the lesion, suggestive of intratumoural hetero-
geneity. These cases were classified as abnormal as well. If neither
tumour nor normal cells showed definite nuclear reactivity above
any cytoplasmic background, the case was considered equivocal.
Cases were judged to show aberrant accumulation of p53 when
10% or more of tumour cell nuclei displayed moderate to strong
immunoreactivity for p53 (Esrig et al, 1994). Slides stained for
cyclin D1 were graded as low expression (< 5% of tumour cell
nuclei showing weak immunoreactivity) or strong expression (5%
or more of tumour cell nuclei showing moderate to strong
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Figure 2 Tumour suppressor gene expression in a biphenotypic muscle invasive transitional cell carcinoma. Left panels: one area near the surface of the
tumour; right panels: a different area closer to the centre of the tumour. (A, B) p16INK4a stains. Note absence of nuclear staining in the tumour cells in (B), with
strong nuclear and cytoplasmic staining (dark brown) in admixed stromal cells (arrows). (C, D) Rb stains. In (C), the tumour is completely negative, while normal
endothelial cells show strong nuclear staining (arrows). (E, F) p53 stains. In (E), most tumour cells show strong nuclear overexpression. Original magnification
4003 (A–F)immunoreactivity for cyclin D1). This cut-off was selected since
normal tissues sometimes showed weak nuclear immunoreactivity
for cyclin D1 in less than 5% of nuclei. All negative control
sections were verified to be non-reactive.
Statistical methods
Summary statistics consisted in mean, median, standard deviation
for continuous, and number and percentages for categorical vari-
ables. Groups were compared by c2 test or Fisher’s exact test with
respect to categorical parameters. The log-rank test was used to
compare groups with respect to their survival experience. Since
this was an elderly population, only death due to or with disease
was treated as endpoint of interest while death due to other causes
and survival to the end of the study were considered censoring
mechanisms. Survival plots were constructed according to the
Kaplan–Meier method. They terminate either with the last death or
when there are fewer than ten survivors left. Stepwise Cox regres-
sion was applied to determine which combination of parameters
would best describe survival, and in particular, to examine whether
cyclin D1 provided additional information. All statistical testing
was for the two sided alternative. P-values less than or equal to
0.05 were considered indicative of a statistically significant effect.
No adjustment for multiple testing was made. The statistical soft-
ware, SAS, on a mainframe computer at the University of
Minnesota was used for statistical analyses (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
Approximately half of the invasive transitional cell carcinomas
examined in this series showed loss of either p16INK4a or Rb
protein. Twenty-three of 79 carcinomas (29%) showed loss of Rb
protein from tumour cell nuclei, while staining for Rb was retained
in adjacent normal tissue (endothelial and stromal cells). In three
cases, loss of Rb was focal, in that other areas of tumour showed
nuclear staining; but stromal cells in the area of negative tumour
showed appropriate staining. These cases were counted as Rb-
abnormal. Fifteen of 79 carcinomas (all Rb-positive) showed
absence of nuclear p16INK4a, with p16INK4a immunoreactivity visible
in at least some adjacent normal cells (Figure 1A). In general,
p16INK4a staining of normal cells and Rb-normal tumours was
weak, as previously noted (Geradts et al, 1995) (Figure 1B). By
contrast, Rb-deleted carcinomas often showed moderately to
markedly increased nuclear staining for p16INK4a (Figure 1C),
consistent with previous reports that Rb is a negative regulator of
p16INK4a transcription, and that loss of Rb function is associated
with elevated levels of p16INK4a protein (Serrano et al, 1993; Li et
al, 1994; Parry et al, 1995). One Rb+ carcinoma was equivocal for
p16INK4a. Finally, one interesting carcinoma showed tumour hetero-
geneity, with inverse patterns of Rb and p16INK4a loss in separate
blocks of tumour (Figure 2). Certain tumour blocks reproducibly
showed nuclear Rb immunoreactivity with loss of p16INK4a staining
in tumour cells, whereas other blocks reproducibly showed Rb loss
in tumour cells with up-regulated p16INK4a expression. The blocks
with Rb deletion and retained p16INK4a also showed abnormal accu-
mulation of p53 protein, while Rb+p16INK4a-negative blocks did
not stain for p53 (Figure 2E,F). Neither area displayed overexpres-
sion of cyclin D1.
Overall, 39/79 carcinomas (49%) showed loss of Rb (29%) or
p16INK4a (19%), or a mixed pattern of loss of one or the other
protein in all blocks tested (1%). One additional carcinoma was
p16INK4a equivocal (Rb+). The inverse relationship between loss of
p16INK4a and loss of Rb was statistically significant (P = 0.004 by
Fisher’s exact test) (Table 2).
Normal cells either showed no detectable staining for cyclin D1
by immunohistochemistry, or showed weak staining of rare nuclei,
with immunoreactivity for cyclin D1 in < 5% of cell nuclei.
Among the invasive transitional cell carcinomas comprising our
series, 58 (73%) displayed minimal or no staining for cyclin D1,
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Table 2 Correlation of Rb and p16 or cyclin D1 expression
p16a cyclin D1
NA N A
Rb N 39 15 34 21
A 23 0 24 0
P = 0.004b P = 0.0002b
N = normal expression; A = abnormal expression (loss of expression for RB,
p16; high level of expression for cyclin D1). aOne additional case was
indeterminate for p16INK4a, and one case was biphenotypic (not included in
this analysis). bP-values were determined by Fisher’s exact test.
Table 3 Cell cycle proteins and invasive bladder carcinomas: percentage of
cases with abnormalities of cell cycle-associated and tumour suppressor
proteins
Variable Normal Abnormal Equivocal
p53 29 (37%) 50 (63%) –
Rb 55 (70%) 24d (30%) –
p16 62 (79%) 16d (20%) 1 (1%)
p16+Rba 39 (49.5%) 39 (49.5%) 1 (1%)
cyclin D1 58 (73%) 21 (27%) –
p16+Rb+cyclin D1b 24 (30%) 55 (70%) –
All variablesc 12 (15%) 67 (85%) –
(p16/Rb/cyclinD1/p53)
p53, p53 protein; Rb, retinoblastoma protein; p16, p16INK4a protein.
aAbnormal = loss of either Rb or p16; bAbnormal = loss of Rb or p16, or
overexpression of cyclin D1; cAbnormal = loss of Rb or p16, or
overexpression of cyclin D1; or accumulation of p53 product; dIncludes a
biphenotypic carcinoma with mirror-image areas of Rb and p16 deletion.
Figure 3 Example of transitional cell carcinoma with strong overexpression
of cyclin D1. In this field, the majority of tumour cells show nuclear reactivity,
which ranges in intensity from weak to strong. Original magnification 4003while 21 (27%) showed cyclin D1 overexpression with strong
staining of 5% or more of tumour cell nuclei (Figure 3). Usually,
between 5% and 50% of nuclei were labelled in the cyclin D1
overexpressors. Strong immunoreactivity for cyclin D1 was
inversely correlated with loss of Rb protein; all of the 21 cyclin D1
overexpressors were Rb+, while none of the 23 Rb– carcinomas
overexpressed cyclin D1. The inverse relationship between cyclin
D1 overexpression and Rb protein loss was statistically significant
(P = 0.0002 by Fisher’s exact test) (Table 2). By contrast, cyclin
D1 overexpression occurred among p16INK4a-negative as well as
p16INK4a-positive carcinomas. Strong cyclin D1 expression was
seen in 6/15 p16INK4a-negative carcinomas (40%) as well as in
14/62 p16INK4a-conserved tumours (23%) (P = 0.23 by c2 test).
Overall, 55/79 carcinomas (70%) showed abnormalities in Rb,
p16INK4a, and/or cyclin D1 expression, while 24 carcinomas (30%)
had a normal staining pattern for all three proteins (Table 3).
Abnormal p53 accumulation occurred in 50/79 carcinomas
(63%). p53 abnormalities were not significantly correlated with
Rb, p16INK4a, or cyclin D1 status (data not shown). In our series,
12/79 carcinomas (15%) showed no detectable abnormalities in
any of the four parameters tested (Table 3).
Using a c2 analysis, we tested p16INK4a, Rb, cyclin D1 and p53
status for correlation with previously reported variables including
TNM stage, grade, DNA ploidy, S phase fraction, percentage of
PCNA-positive nuclei, and EGFR status. There was a weak asso-
ciation between Rb loss and an elevated PCNA score (P = 0.04).
No other associations between PCNA/S phase fraction and
Rb/p16INK4a/cyclinD1/p53 could be identified in our series;
however, only 35 patients had flow histograms interpretable for S
phase fraction. High-grade carcinomas (grade 4 out of 4) were
more likely to have lost p16INK4a protein than were grade 2 + grade
3 carcinomas (35% v 13% of tumours, P = 0.027 by c2 test). Grade
1180 GA Niehans et al
British Journal of Cancer (1999) 80(8), 1175–1184 © 1999 Cancer Research Campaign 
CyD
High
Low
0 20 40 60 80 100 120
Time since surgery (months)
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Rb
Abnormal
Normal
0 2 04 06 08 0 1 0 0 1 2 0
Time since surgery (months)
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
p16
0 20 40 60 80 100 120
Time since surgery (months)
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
p53
Abnormal
Normal
0 2 04 06 08 0 1 0 0 1 2 0
Time since surgery (months)
1.0
0.8
0.6
0.4
0.2
0.0
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Abnormal
Normal
Figure 4 Kaplan–Meier curves for survival with respect to death of or with disease. Plots terminate when there are fewer than ten patients followed or with the
last death. (A) Cyclin D1: low (normal) versus high expression; low group contains 58 patients, high group 21 patients. (B) Rb: normal (55 patients) versus
abnormal (24 patients). (C) p16INK4a: normal (62 patients) versus abnormal (16 patients). (D) p53: normal (29 patients) versus abnormal (50 patients). Cyclin D1
(CyD) P = 0.02; for all the other comparisons, P > or = 0.2 according to log-rank statistics4 carcinomas were also slightly more likely to show Rb loss than
were lower grade carcinomas (39% v 25%, P = 0.23). Combining
these two findings, high-grade (grade 4) carcinomas were signifi-
cantly more likely to show deletion of one of these two proteins
than were grade 2 + grade 3 carcinomas (74% v 40%, P = 0.006 by
c2 test) (Table 4). Conversely, lower-grade carcinomas were more
likely to show strong cyclin D1 overexpression than were grade 4
carcinomas (34% v 9%, P = 0.021) (Table 4). Abnormal p53 accu-
mulation was slightly more common among grade 2 + 3 carci-
nomas, but did not reach statistical significance (68% vs 52%,
P = 0.19). There were no significant associations between
Rb/p16INK4a/cyclin D1/p53 status and TNM stage and ploidy. There
was a weak association between Rb loss and staining for EGFR
(P = 0.046). No other significant associations were found between
Rb/p16INK4a/cyclin D1/p53 and EGFR immunoreactivity.
Disease-specific survival was analysed by log-rank test
according to Rb, p16INK4a, cyclin D1 and p53 status, the presence
or absence of any abnormality in Rb, p16INK4a, or cyclin D1, or the
presence or absence of any abnormality in any of the four tested
variables. Strong cyclin D1 overexpression was associated with
better survival (P = 0.02 by log-rank test, when compared to
weak/negative staining) (Figure 4A). Neither Rb, p16INK4a, nor p53
status were significantly correlated with length of survival in this
series (P = 0.2, 0.8 and 0.3 respectively) (Figure 4 b–d). No statis-
tically significant survival difference was detected between
patients whose tumours had a normal phenotype for cyclin D1, Rb,
p16INK4a and p53, versus those whose tumours showed one or more
abnormalities in these cell cycle proteins (Table 5). The analyses
were repeated restricted to muscle-invasive (T2–T4) carcinomas.
Again, cyclin D1 overexpression was associated with improved
survival (P = 0.02, data not shown), while Rb, p16INK4a,
Rb+p16INK4a and p53 status did not show a significant correlation
with outcome (P = 0.3, 0.6, 0.6 and 0.3 respectively).
By multivariate analysis, TNM stage and cyclin D1 status were
independently associated with disease-specific survival. No other
variable significantly affected survival in multivariate analysis
(Table 6).
DISCUSSION
Loss or dysregulation of key components of the G1 cell cycle
restriction point is a frequent event in human bladder carcinoma,
occurring in two-thirds of the invasive transitional cell carcinomas
studied in this series. While loss of Rb protein (Cordon-Cardo et
al, 1992; Logothetis et al, 1992; Jahnson et al, 1995; Lipponen and
Liukkonen, 1995; Têtu et al, 1996; Cote et al, 1998), deletions
of the p16INK4a gene (Orlow et al, 1995; Packenham et al, 1995;
Williamson et al, 1995), and cyclin D1 overexpression (Bringuier
et al, 1996; Lee et al, 1997; Shin et al, 1997) have previously been
reported in transitional cell carcinomas, this is the first large study
to examine loss of p16INK4a at the more sensitive protein level, and
to document the interrelationship of changes in each of these three
components of the G1 checkpoint in the same set of bladder
cancers.
Loss of Rb and p16INK4a proteins can occur in malignant cell
lines that have retained mRNA expression and do not have
obvious abnormalities of the gene at the DNA level. For example,
examination of small-cell carcinoma lines revealed structural
abnormalities of the Rb gene in only 18% of cell lines, with
absence of Rb mRNA in 60% of these cell lines and loss of Rb
protein in eight of the nine lines with retained mRNA (Harbour et
al, 1988; Horowitz et al, 1990). Similarly, loss of p16INK4a protein
was detected in 23/29 tumour cell lines of diverse origin (79%),
whereas abnormalities of mRNA expression were identified
in only 43% of the same cell lines (Okamoto et al, 1994).
Immunohistochemistry offers a means of assessing the presence or
loss of Rb and p16INK4a protein within malignant cells using
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Table 4 Correlation of histologic grade and expression of p16/Rb or cyclin
D1
p16 p16 or Rb cyclin D1
NA N A N A
Grade 2/3 49 7 34 22 37 19
41 5 8 6 1 7 2 1 2
P = 0.027 (c2) P = 0.006 (c2) P = 0.021 (c2)
N = normal expression; A = abnormal expression (loss of expression for Rb;
high level of expression for cyclin D1; for p16 or Rb, loss of either protein
was counted as abnormal).
Table 5 Univariate survival analysis
Potential predictive variable P-value
Age (continuous) 0.9
Grade (2/3 vs 4) 0.007
TNM Stagea (1, 2, 3, 4) 0.0001
EGFR indexb (low vs high) 0.03
Cyclin D1 (low vs high) 0.02
Rb (normal vs abnormal) 0.2
p16 (normal vs abnormal) 0.8
p53 (normal vs abnormal) 0.3
p16+Rb (normal vs abnormalc) 0.14
p16+Rb+cyclin D1 (normal vs abnormald) 0.2
All variables (normal vs abnormale) 0.9
(p16/Rb/cyclinD1/p53)
EGFR, epidermal growth factor receptor; p53, p53 protein; Rb,
retinoblastoma protein; p16, p16INK4a protein. Age (continuous) was analysed
by Cox regression. Other variables were analysed by log-rank test. aTNM
staging was performed according to the American Joint Committee on
Cancer (1992), Manual for staging cancer, 4th edn; bEGFR index was
determined in a previous publication (Nguyen et al, 1994); cAbnormal = loss
of either Rb or p16; dAbnormal = loss of Rb or p16, or overexpression of
cyclin D1; eAbnormal = loss of Rb or p16, or overexpression of cyclin D1, or
accumulation of p53 product.
Table 6 Multivariate survival analysis
Coefficient Wald’s Relative Overall significance
(s.e.m.) P-value hazard of model
Model 1
Grade – 0.4
EGFR –0.77 (0.42) 0.07 2.16
CyD –1.61 (0.74) 0.03 0.2 P = 0.003
Model 2
TNM stage 1.283 (0.301) 0.0001 3.61
CyD –1.95 (0.75) 0.009 0.14 P = 0.0001
Stepwise selection from parameters which had P <0.2 in univariate analyses.
Grade: 2 & 3 versus 4. EGFR: epidermal growth factor receptor (low vs high).
CyD: cyclin D1 (low vs high). TNM stage (1 vs 2 vs 3 vs 4). TNM stage
determined according to the Manual for Staging of Cancer, 4th ed. (American
Joint Committee on Cancer, 1992).archival material, with adjacent stroma and normal epithelium
serving as internal positive controls for adequacy of antigenic
preservation.
We identified loss of Rb protein in 29% of invasive transitional
cell carcinomas of the bladder treated by cystectomy (23/79 cases).
This correlates well with the frequency of Rb protein loss reported
in other series, which has ranged from 16% to 46% (Cordon-Cardo
et al, 1992; Logothetis et al, 1992; Jahnson et al, 1995; Lipponen
and Liukkonen, 1995; Têtu et al, 1996; Cote et al, 1998). We also
identified loss of the p16INK4a tumour suppressor gene product in
15/79 carcinomas (19%). Homozygous deletion of the p16INK4a gene
has been reported in 10–22% of primary bladder transitional cell
carcinomas (Orlow et al, 1995; Packenham et al, 1995; Williamson
et al, 1995). In our series of bladder cancers, loss of Rb and p16INK4a
proteins were mutually exclusive events, including one bipheno-
typic case where several tumour blocks showed a p16INK4a+Rb-
phenotype, while other tumour blocks showed a mirror image
p16INK4a-Rb+ phenotype (Figure 1). The p16INK4a+Rb2 blocks
showed strong staining for accumulated p53 protein, while
p16INK4a2Rb+ blocks were p53-negative, suggesting that this
tumour was biclonal. Conventional molecular analysis would have
missed this striking example of tumour heterogeneity.
Inverse relationships between loss of p16INK4a and Rb have been
previously reported in melanomas (Bartkova et al, 1996), glio-
blastomas (Ueki et al, 1996), lung carcinomas (Otterson et al,
1994; Shapiro et al, 1995; Kratzke et al, 1996; Sakaguchi et al,
1996), pancreatic carcinomas (Schutte et al, 1997), mesotheliomas
(Kratzke et al, 1995), breast carcinomas (Geradts et al, 1995) and a
variety of neoplastic cell lines (Aagaard et al, 1995). Double loss
of p16INK4a and Rb proteins occurs, but is rare (Otterson et al, 1994;
Kratzke et al, 1996). Experimentally, functional Rb protein is
required in order for p16INK4a to be able to suppress growth (Lukas
et al, 1995c; Medema et al, 1995). In Rb-deleted tumours, there
may be little selective advantage accruing to cells that also lose
p16INK4a (Aagaard et al, 1995).
We identified strong overexpression of cyclin D1 protein in
27% of invasive transitional cell carcinomas of the bladder (21/79
cases). We could not determine by immunohistochemistry alone
whether the cyclin D1 gene was amplified or transcriptionally
overexpressed. Again, there was an inverse relationship between
cyclin D1 overexpression and Rb protein loss. Each of the 21
cyclin D1 overexpressors had retained Rb protein; correspond-
ingly, none of the 23 Rb-negative tumours showed strong cyclin
D1 staining. An inverse relationship between cyclin D1 amplifica-
tion/overexpression and Rb protein loss has also been reported in
lung carcinoma cell lines (Schauer et al, 1994) and in oesophageal
carcinomas (Jiang et al, 1993). As is the case with p16INK4a, exper-
imental studies suggest that loss of Rb protein commits cells to
ongoing proliferative cycles regardless of the cellular level of
cyclin D1 (Tam et al, 1994; Lukas et al, 1995b).
Conversely, we often found cyclin D1 overexpression in
p16INK4a-negative carcinomas, and vice-versa. Lukas et al have
reported that abnormalities of cyclin D1 and p16INK4a often occur
concomitantly in human cancer cell lines (Lukas et al, 1995a).
Experimentally, they were able to demonstrate in human diploid
fibroblast strains that microinjection of GST-p16INK4a protein and a
neutralizing antibody to cyclin D1 synergistically enhanced G1
arrest, leading them to hypothesize that in Rb-competent cells it is
the balance between functional cyclin D1 and p16INK4a which
determines whether or not cells will proceed through the G1
checkpoint (Lukas et al, 1995a). Our results are consistent with
their conclusion that while Rb defects eliminate the G1 checkpoint
completely, aberrations of the upstream components such as
p16INK4a and cyclin D1 can cooperate in multistep tumorigenesis.
While wild-type p53 has a short half-life and is normally
present at low levels in the cell, mutant p53 proteins often form
complexes with heat shock protein 70 and accumulate within cells
(Finlay et al, 1988). Nuclear immunoreactivity for p53 protein has
been used as a surrogate marker for p53 mutation, on the assump-
tion that accumulated p53 protein is likely mutant. Cordon-Cardo
et al compared immunohistochemical reactivity for p53 protein in
42 bladder tumours with single-strand conformation polymor-
phism (SSCP) genetic analysis followed by sequencing, and calcu-
lated that immunohistochemistry was 90.3% accurate in detecting
p53 mutations (Cordon-Cardo et al, 1994). By immunohistochem-
istry, we identified abnormal nuclear accumulation of presumably
mutant p53 protein in 50/79 invasive bladder carcinomas (63%).
There was no association between abnormal p53 staining and
abnormalities in the Rb/p16INK4a/cyclin D1 pathway.
Univariate survival analysis of our series of 79 invasive transi-
tional cell carcinomas of the bladder treated by cystectomy
showed that only TNM stage, grade, EGFR index (from Nguyen et
al, 1994) and cyclin D1 overexpression were significantly related
to disease-specific survival (Table 5). Unexpectedly, cyclin D1
overexpression was associated with lower grade and better
survival, and the favourable prognostic significance of cyclin D1
overexpression persisted in multivariate Cox regression analysis
after correction for stage (Table 6). A similar association between
cyclin D1 overexpression and favourable outcome has recently
been reported for a large series of breast carcinomas (Gillett et al,
1996). Previous studies of bladder carcinoma have suggested that
overexpression of cyclin D1 is more common in superficial than
invasive bladder neoplasms (Bringuier et al, 1996; Lee et al,
1997). Among superficial bladder tumours, cyclin D1 overexpres-
sion has been linked to increased risk for local recurrence but not
for tumour invasion (Shin et al, 1997). In our series of invasive
carcinomas, the survival advantage of patients with cyclin D1-
overexpressing neoplasms did not appear to be due to a lower
tumour cell proliferation rate, since cyclin D1 status did not corre-
late with either S phase fraction or percentage of PCNA-positive
nuclei. Instead, it is possible that an increased cellular level of
cyclin D1 enhances other processes such as apoptosis which limit
tumour growth. In this context, it is interesting that head and neck
carcinomas with the highest levels of cyclin D1 expression also
display the highest percentage of apoptotic cells when subjected to
in-situ end labelling (Kotelnikov et al, 1997). Conversely, bladder
carcinomas with G1 checkpoint aberrations other than cyclin D1
overexpression could have a higher frequency of mutations that
promote tumour spread (e.g. a pro-metastatic phenotype).
Although high-grade (grade 4) neoplasms were more likely to
be deficient in either p16INK4a or Rb protein than were their lower
grade counterparts (74% abnormal phenotype for grade 4 carci-
nomas versus 40% for grade 2/3 carcinomas, P = 0.006), neither
Rb, p16INK4a, nor combined Rb/p16INK4a status reached statistical
significance as a predictor of survival in our series. The relation-
ship between p16INK4a protein expression and outcome in bladder
carcinoma has not been previously studied, although one report
suggested that bladder carcinomas with deletion of the p16INK4a
gene are generally of low stage and grade (Orlow et al, 1995). A
number of previous papers have reported shorter survival times
among patients with Rb-deleted bladder carcinomas (Cordon-
Cardo et al, 1992; Logothetis et al, 1992; Lipponen and
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found such an association (Jahnson et al, 1995; Têtu et al, 1996).
In our series, there was a trend toward poorer outcome for Rb-
deleted tumours (Figure 4; P = 0.2), which might well have
reached significance with a larger cohort. We did not find any link
between p16INK4a status and outcome. Based upon previous studies
(Lipponen, 1993; Sarkis et al, 1993; Esrig et al, 1994; Cote et al,
1998), we anticipated poorer survival among patients with
p53-abnormal tumours, although other groups have published
conflicting results (Jahnson et al, 1995; Vet et al, 1995; Glick et al,
1996). We did not find an association between abnormal p53
protein accumulation and poor outcome among our cohort of
patients with invasive transitional cell carcinomas treated by
cystectomy. We utilized monoclonal antibody D07 to detect p53
accumulation, whereas most previous series, regardless of whether
or not they found an association between p53 status and survival,
utilized clone p1801. In a previous study (Resnick et al, 1995), we
found that D07 and p1801 were equally sensitive in detecting p53
accumulation in paraffin sections from lung and head and neck
cancers. It is possible, however, that technical factors played a role
in these divergent results. Alternately, differences in patients popu-
lations between series (such as relative frequency of early- versus
late-stage disease, average patient age, carcinogen exposures, etc.)
might have affected both the frequency and prognostic signifi-
cance of p53 mutation.
One-third of the tumours in our series did not show detectable
abnormalities of p16INK4a, Rb, or cyclin D1 expression, even
though loss of the G1 restriction point appears to be a hallmark of
neoplastic disease. These ‘normal phenotype’ tumours showed no
differences in proliferation indices or outcome when compared to
tumours that had at least one abnormal staining pattern. One possi-
bility is that some tumours expressed mutated non-functional
p16INK4a or Rb that nonetheless was immunoreactive on immuno-
histochemical analysis. A second possibility is that mutations in
other proteins dysregulated the G1 checkpoint complex. For
example, mutations in CDK4 have been reported in melanoma cell
lines and in familial melanoma kindreds; these mutations prevent
the CDK4–cyclin D1 complex from interacting with the inhibitory
p16INK4a protein (Bartkova et al, 1996; Zuo et al, 1996; Tsao et al,
1998). Testing for genomic mutations would optimally be
performed on fresh or frozen tissue, which is not available for this
archival cohort.
In summary, in our series most, although not all, bladder carci-
nomas had detectable abnormalities in one or more components of
the Rb/p16INK4a/cyclin D1 cell cycle checkpoint. While cyclin D1
and p16INK4a abnormalities were often seen in the same tumours,
we found a strong inverse correlation between p16INK4a/cyclin D1
abnormalities and loss of the Rb protein, as has been reported for
other neoplasms. Abnormal accumulation of p53 protein was
common, occurring in 63% of our cases, and was not correlated
with the presence or absence of cyclin D1 overexpression, or
p16INK4a and Rb loss. In this series, only TNM stage and cyclin D1
overexpression reached significance as independent predictors of
disease-free survival. Cyclin D1 overexpression appeared to occur
in a subset of lower grade, less aggressive carcinomas with a rela-
tively favourable prognosis.
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